These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Pummer K; Lehnert M; Stettner H; Hubmer G Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791 [TBL] [Abstract][Full Text] [Related]
3. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T; J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218 [TBL] [Abstract][Full Text] [Related]
4. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer]. Ito T; Aizawa T; Yamamoto S; Ohkubo Y; Tsujino S; Miki M Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601 [TBL] [Abstract][Full Text] [Related]
5. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272 [TBL] [Abstract][Full Text] [Related]
6. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate]. Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044 [TBL] [Abstract][Full Text] [Related]
7. [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT]. Sumiyoshi Y; Hashine K; Kuwahara M; Aki M; Yamamoto A; Akazawa S; Takenaka A Gan To Kagaku Ryoho; 1999 Jul; 26(8):1153-8. PubMed ID: 10431581 [TBL] [Abstract][Full Text] [Related]
8. [Progress of endocrine therapy for prostate cancer and results]. Kanetake H Gan To Kagaku Ryoho; 1996 Mar; 23(4):413-7. PubMed ID: 8678491 [TBL] [Abstract][Full Text] [Related]
9. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989 [TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Raina R; Pahalajani G; Agarwal A; Zippe C Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592 [TBL] [Abstract][Full Text] [Related]
11. [Usefulness and positioning of MAB therapy for prostate cancer]. Akaza H; Chodak GW; Hirao Y Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758 [TBL] [Abstract][Full Text] [Related]
12. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. Miyake H; Hara I; Eto H BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202 [TBL] [Abstract][Full Text] [Related]
20. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer. Akaza H BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]